United Therapeutic (UTHR) 122.28 $UTHR United

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
United Therapeutic (UTHR) 122.28 $UTHR

United Therapeutics Falls 2.03% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Aug 26, 2:01PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $119.70 to a high of $124.80. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $121.64 on volume of 266,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 122.28 (+0.37)

Look for Shares of United Therapeutics to Potentially Rebound after Yesterday's 2.03% Sell Off
Comtex SmarTrend(R) - Fri Aug 26, 2:00PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $119.70 to a high of $124.80. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $121.64 on volume of 266,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
UTHR: 122.28 (+0.37)

Drug Makers Stocks Under Scanner -- Amarin, Depomed, United Therapeutics, and Sucampo Pharma
PR Newswire - Tue Aug 16, 6:40AM CDT
In today's pre-market research, Stock-Callers.com follows four Drug Manufacturing equities, namely, Amarin Corp. PLC (NASDAQ: AMRN), Depomed Inc. (NASDAQ: DEPO), United Therapeutics Corp. (NASDAQ: UTHR), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Global prescription drug sales are expected to increase 3% this year despite drug-price debates and cost-control pressures. You can access of our complimentary research reports on these stocks now at:
UTHR: 122.28 (+0.37), AMRN: 2.80 (+0.01), SCMP: 10.96 (-0.05), DEPO: 20.29 (+0.24)

Cempra Appoints Dr. David Zaccardelli to Board of Directors
GlobeNewswire - Thu Aug 11, 3:05PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that the company has appointed David Zaccardelli, Pharm.D. to serve on the company's board of directors.
UTHR: 122.28 (+0.37), CEMP: 21.94 (+0.50)

United Therapeutics Corporation To Present At The 2016 Wedbush PacGrow Healthcare Conference
PR Newswire - Wed Aug 10, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 2016 Wedbush PacGrow Healthcare Conference in New York City.
UTHR: 122.28 (+0.37)

SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 3.53% Gain
Comtex SmarTrend(R) - Mon Aug 01, 2:37PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.01 to a high of $126.65. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $122.23 on volume of 483,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 122.28 (+0.37)

Watch for United Therapeutics to Potentially Pullback After Gaining 3.53% Yesterday
Comtex SmarTrend(R) - Mon Aug 01, 2:35PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $121.01 to a high of $126.65. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $122.23 on volume of 483,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 122.28 (+0.37)

SmarTrend Watching for Potential Pullback in Shares of United Therapeutics After 4.98% Gain
Comtex SmarTrend(R) - Thu Jul 28, 2:49PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $112.73 to a high of $118.98. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $114.12 on volume of 448,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 122.28 (+0.37)

Watch for United Therapeutics to Potentially Pullback After Gaining 4.98% Yesterday
Comtex SmarTrend(R) - Thu Jul 28, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $112.73 to a high of $118.98. Yesterday, the shares gained 5.0%, which took the trading range above the 3-day high of $114.12 on volume of 448,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 122.28 (+0.37)

United Therapeutics Corporation Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Jul 28, 5:00AM CDT
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the second quarter ended June 30, 2016.
UTHR: 122.28 (+0.37)

Nivalis (NVLS): Can the Stock Surprise This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 5:46PM CDT
Nivalis Therapeutics (NVLS), which is expected to report second-quarter 2016 results on Aug 1, posted a negative surprise of 15.91% last quarter.
VRTX: 94.51 (-1.29), NVLS: 6.39 (+0.08), UTHR: 122.28 (+0.37), BMY: 57.39 (+0.15)

Featured Research Report on Drug Manufacturers Stocks
ACCESSWIRE - Tue Jun 14, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 14, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Drug Manufacturers-Other industry. Companies recently under review include Ionis Pharma, Depomed, Amarin, and United Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
UTHR: 122.28 (+0.37), AMRN: 2.80 (+0.01), DEPO: 20.29 (+0.24), IONS: 29.65 (-0.04)

United Therapeutics Rises 1.86% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Jun 02, 2:47PM CDT
United Therapeutics (NASDAQ:UTHR) traded in a range yesterday that spanned from a low of $118.58 to a high of $121.69. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $119.59 on volume of 230,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
UTHR: 122.28 (+0.37)

Downgrade Alert for United Therapeutics (UTHR)
Comtex SmarTrend(R) - Wed May 25, 3:38AM CDT
United Therapeutics (NASDAQ:UTHR) was downgraded from Buy to Hold at Argus Research today. The stock closed yesterday at $116.62 on volume of 639,000 shares, below average daily volume of 888,000. United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
UTHR: 122.28 (+0.37)

United Therapeutics Partnering Deals and Alliances 2010 to 2016
PR Newswire - Tue May 24, 3:47PM CDT
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world's leading life sciences companies.
UTHR: 122.28 (+0.37)

Crosswind PR Issues Correction to May 9 Press Release
PRWeb - Tue May 10, 3:10PM CDT
Crosswind Media & PR issues the following correction to a press release issued May 9, 2016. The press release titled, "United Therapeutics Selects HCB Health as Agency of Record for Remodulin," was printed in error. This is now removed from online news sources and outlets. Crosswind Media & PR takes full responsibility for this error. This was not an error made by our client, HCB Health, nor the fault of PRWeb. Moreover, the press release was not reviewed or approved by United Therapeutics Corporation.
UTHR: 122.28 (+0.37)

3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 20.70 (-0.19), GILD: 78.38 (+0.46), MRK: 62.79 (+0.08), UTHR: 122.28 (+0.37)

United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 26.65 (-0.41), UTHR: 122.28 (+0.37), AEGR: 1.63 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading